996d8c98-529a-4438-9db5-d49ff575af45
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.530
- ANDROGEN_RESPONSE+0.400
- HEME_METABOLISM+0.360
- UV_RESPONSE_DN+0.260
- FATTY_ACID_METABOLISM+0.240
- ADIPOGENESIS+0.210
- CHOLESTEROL_HOMEOSTASIS+0.210
- COMPLEMENT+0.190
- APICAL_SURFACE+0.170
- ESTROGEN_RESPONSE_EARLY+0.160
Top 10 suppressed
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V2-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- MYC_TARGETS_V1-0.380
- ANGIOGENESIS-0.230
- MYOGENESIS-0.230
- DNA_REPAIR-0.220
- WNT_BETA_CATENIN_SIGNALING-0.160
- UV_RESPONSE_UP-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475121 | — | — | 0.861 |
| 2 | 0429cf04-6e5c-41dd-b4a9-4f7ad15d15bc | — | — | 0.829 |
| 3 | BS_3Q0GTSYH | pilocytic astrocytoma | — | 0.819 |
| 4 | BS_CTR5X93B | pilocytic astrocytoma | — | 0.789 |
| 5 | 12b633ae-2a36-40b0-a4a3-c1d5f021fa23 | — | — | 0.785 |
| 6 | BS_66ABA973 | pilocytic astrocytoma | — | 0.781 |
| 7 | SRR12475139 | — | — | 0.775 |
| 8 | SRR23036898 | — | — | 0.770 |
| 9 | BS_Y0PCBNJV | pilocytic astrocytoma | — | 0.770 |
| 10 | BS_GHNJ4CYC | low-grade glioma | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.530 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.360 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |